Close

Amgen (AMGN) Receives FDA Approval for ENBREL sBLA as Expanded Indication

November 7, 2016 7:30 AM EST Send to a Friend
Amgen (Nasdaq: AMGN) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login